Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lasofoxifene + abemaciclib versus fulvestrant + abemaciclib in ESR1-mutant ER-positive/HER2-negative advanced breast cancer
ChiCTR2400090280Phase 3Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing Lasofoxifene + abemaciclib with Fulvestrant + abemaciclib (2 arms). Primary endpoint: Progression-free survival. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
lasofoxifeneabemaciclibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2400090280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090280.